# VISION (NCT02864992)

> Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02864992
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Conditions: Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Lung Adenocarcinoma Stage IIIB/IV
- Interventions: Tepotinib
- Enrollment: 337
- Primary outcome: Part 1: Cohort A: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Review Committee (IRC)
- Primary outcome: Part 1: Cohort B: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC)
- Primary outcome: Part 2: Cohort C: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC)

## Indexed commentary on VISION so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=vision-nct02864992